ArticleScientific reports2025
Evaluation of genotype matched recombinant DNA vaccine for protection against genotype VII velogenic Newcastle disease virus in Pakistan.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newcastle disease virus (NDV) remains a major threat to the poultry industry worldwide. Recombinant DNA vaccine against NDV offers a promising solution to current Newcastle disease (ND) challenges. Present study describes the development of a DNA vaccine (rDNA-NDV-F) using the fusion (F) gene from NDV genotype VII strain isolated from Rawalpindi, Pakistan. While conventional NDV vaccines reduce mortality in commercial poultry, they do not provide complete protection or prevent viral shedding. To address this issue, genotype-matched vaccines have been proposed. Here, we developed and evaluated the efficacy of the rDNA-NDV-F vaccine against genotype VII challenge. NDV was isolated from a field strain and propagated in embryonated chicken eggs (ECE). Virus activity was confirmed using Hemagglutination assay (HA), HA inhibition (HAI), and Mean Death Time (MDT) assay. Polymerase Chain Reaction (PCR) and sequencing confirmed the genotype VII.2 strain. The DNA vaccine was constructed using the fusion (F) protein gene cloned into the expression plasmid pcDNA3.1. Gene insertion was verified by PCR and restriction digestion, while protein expression was confirmed via immunofluorescence assay. To assess vaccine efficacy, 120 chickens (14 days old) were divided into four groups: G1 (rDNA-NDV-F), G2 (empty vector), G3 (PBS control), and G4 (non-vaccinated, non-challenged control). Serological responses were measured using ELISA on days 0, 7, 14, 21, and 28. Birds were challenged with NDV genotype VII (10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.